NAPL Napo Pharm.Regs

RNS Number:0265Q
Napo Pharmaceuticals Inc
13 March 2008


For immediate release                                              13 March 2008


                           Napo Pharmaceuticals, Inc

                           ("Napo" or the "Company")


                               Admission to CREST


South San Francisco, California, 13 March 2008 - Napo Pharmaceuticals, Inc,
which focuses on the development and commercialisation of proprietary
pharmaceuticals for the global marketplace in collaboration with local partners,
is pleased to announce that, with effect from 14 March 2008 (the "Effective
Date"), Napo shareholders will be able to hold and transfer Napo's common shares
within the CREST system as depository interests, as long as certain criteria are
satisfied.


The Company, through its registrar, Computershare Investor Services (Channel
Islands) Limited (the "Registrar"), has established a depository interest
facility to enable qualifying shares (the "Qualifying Shares") to be traded in
electronic form within the CREST system under a new ISIN number. On the
Effective Date, 14,652,800 Qualifying Shares will be transferred to the new ISIN
number. These Qualifying Shares may then be admitted to CREST as depository
interests, thereby allowing settlement of transactions in Qualifying Shares
within the CREST system.


CREST is a UK and Irish electronic paperless share transfer and settlement
system that allows shares and other securities to be held in electronic rather
than paper form. Companies other than UK or Irish companies may not settle their
shares directly through CREST but are required to settle them by means of a
depository interest.


The transferred Qualifying Shares will be represented in CREST by the new ISIN
number US6306081075 (LSE: NAPN). The 39,045,969 common shares of the Company
which are not Qualifying Shares will continue to be represented by ISIN number
USU629901039 (LSE: NAPL).


Common shares will be eligible for settlement through CREST where they were
issued at least twelve months ago, whether in an offering conducted outside the
United States pursuant to Regulation S of the United States Securities Act of
1933, as amended (the "Securities Act") or an offering conducted inside the
United States pursuant to Regulation D of the Securities Act or otherwise, and
where the shareholder is not an affiliate of Napo.


If a shareholder wishes their Qualifying Shares to remain in certificated
format, they will be required to provide their current share certificate to the
Registrar who will then issue a new certificate under the new ISIN. If a
shareholder wishes to transfer their Qualifying Shares into the CREST system,
they should contact their broker or custodian in the first instance.


Shareholders should contact the Registrar on +44 (0)1534 825 294 if they require
further confirmation of whether their shares are Qualifying Shares and the
process for dematerialisation of their Qualifying Shares or for receiving new
share certificates.


For more information please contact:

Napo Pharmaceuticals, Inc.
Lisa Conte, Chief Executive Officer
(001) + 650 616 1902

Charles Thompson, Chief Financial Officer
(001) + 650 616 1903



About Napo

Napo Pharmaceuticals Inc., focuses on the development and commercialisation of
proprietary pharmaceuticals for the global marketplace in collaboration with
local partners. Napo was founded in November 2001, and is based in California,
USA with a subsidiary in Mumbai, India. Napo's late-stage proprietary
gastro-intestinal compound, crofelemer, is in various stages of clinical
development for four distinct product indications, including a late-stage Phase
3 program:

-   CRO-HIV for AIDS diarrhoea, Phase 3;

-   CRO-IBS for diarrhoea irritable bowel syndrome (D-IBS), Phase 2;

-   CRO-ID for acute infectious diarrhoea (including cholera), Phase 2;
    and CRO-PED for paediatric diarrhoea, Phase 1.

The FDA has granted fast-track status to CRO-IBS and CRO-HIV. Crofelemer, a
proprietary patented first in class agent, is extracted from Croton lechleri, a
medicinal plant which can be sustainably harvested from several countries in
South America. Napo has exclusive worldwide rights to synthetic compounds in
pre-clinical development which act by the same mechanism of action. Napo also
plans to develop an early clinical stage product, NP-500, for the treatment of
insulin resistant diseases of Type II diabetes and metabolic syndrome (Syndrome
X; pre-diabetic syndrome) and has 4 issued patents for anti-cancer agents in
pre-clinical development. Napo has a plant library of approximately 2,300
medicinal plants from tropical regions and Napo has entered two screening
relationships associated with this collection. Currently, products are based on
the chemical and biological diversity derived from plants with medicinal
properties, but future products may be in-licensed from other sources. Napo has
partnerships with Glenmark Pharmaceuticals Limited of India and AsiaPharm Group
Ltd. of China.

For more information please visit www.napopharma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCSFMFFDSASEFD

Napo Pharm.Regs (LSE:NAPL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Napo Pharm.Regs (LSE:NAPL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024